Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Exclusion Criteria

• •Participants with unstable cardiac function or evidence of previous myocardial infarction in the past 12 months or any clinically significant active cardiovascular disease that, in the opinion of the Investigator, could interfere with the safety of the participant
• •Any clinically significant conduction abnormality or arrhythmia (including non-sustained or sustained ventricular tachycardia as per Investigator's assessment)
• •Infection with human immunodeficiency virus (HIV), hepatitis A virus (HAV), HBV (positive HBsAg or positive hepatitis B core antibody with negative hepatitis B surface antibody), hepatitis C virus (HCV), HDV or hepatitis E virus (HEV). HCV antibody positive participants with a negative HCV RNA are eligible. HDV antibody positive participants with a negative HDV RNA are eligible
• •Systolic BP is outside the range of 90-160 mmHg, or diastolic BP is outside the range of 45-95 mmHg or heart rate is outside the range of 50-100 beats per minute (bpm) for female participants or 45-100 bpm for male participants at screening
• •Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medication) within 30 days prior to D1 of study participation
• •Not on stable dose and regimen of any medication
• •Acute or worsening chronic hepatitis
• •Participants requiring paracentesis more than once a month
• •Participants with refractory encephalopathy or significant Central Nervous System
• •History of gastric or esophageal variceal bleeding within the past 6 months
• •Participants with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement
• •Presence of hepatopulmonary or hepatorenal syndrome
• •Presence of primarily cholestatic liver diseases
• •History of or currently listed for liver transplantation